SLE

Systemic Lupus Erythematosus (SLE)Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022 - 6:24pm

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the systemic lupus erythematosus (SLE) space target B-cell activating factor, glucocorticoid receptor, corticotropin releasing factor, and corticotropin releasing hormone.
  • The majority of industry-sponsored drugs in active clinical development for SLE are in Phase II, with only one drug in the NDA/BLA phase.
  • GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for SLE, followed by AstraZeneca.

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

Retrieved on: 
Tuesday, January 25, 2022 - 11:32am

ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen (patented nicotinamide riboside, or NR) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation .

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen (patented nicotinamide riboside, or NR) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation .
  • The study was conducted as part of the ChromaDex External Research Program (CERP) and adds to a growing body of clinical evidence supporting the potential anti-inflammatory effects of NR supplementation.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen.

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Retrieved on: 
Tuesday, January 18, 2022 - 12:30pm

BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase 3 clinical trial of its lead product candidate atacicept in lupus nephritis (LN).

Key Points: 
  • BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase 3 clinical trial of its lead product candidate atacicept in lupus nephritis (LN).
  • This announcement comes after positive feedback from the U.S. Food and Drug Administration (FDA)s review of the proposed Phase 3 trial.
  • Vera expects to share full results from the interim analysis in mid-2022 and initiate the next clinical trial in 2023.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study.

‘Rise Above’ – Avolon Publishes 2022 Outlook Paper

Retrieved on: 
Tuesday, January 18, 2022 - 7:00am

Avolon, the international aircraft leasing company, issued its annual outlook paper for 2022 titled Rise Above.

Key Points: 
  • Avolon, the international aircraft leasing company, issued its annual outlook paper for 2022 titled Rise Above.
  • Looking ahead, the strong economic growth forecast for 2022 will drive a further recovery in demand for air travel.
  • In 2022, a strong recovery in international air traffic will follow the domestic air travel rebound of 2021, bouncing back to 70% of 2019-levels by year-end.
  • Outlook for 2030 SAF production quadruples as projects are funded in 2022: Demand for SAF is strong but supply is limited.

BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

Retrieved on: 
Thursday, January 13, 2022 - 9:16am

The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
  • The collaboration has already achieved two major milestones, with the first novel targets added to AstraZeneca's portfolio for both CKD and IPF.
  • Anne Phelan, Chief Science Officer at BenevolentAI, commented, "Our collaboration with AstraZeneca represents the future of drug discovery.
  • Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, commented, "Systemic lupus erythematosus and heart failure are debilitating diseases with high unmet patient needs.

BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

Retrieved on: 
Thursday, January 13, 2022 - 9:17am

LONDON, Jan. 13, 2022 /PRNewswire/ -- BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes an upfront payment, research funding, development milestone payments and tiered royalties on future revenues.

Key Points: 
  • The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
  • The collaboration has already achieved two major milestones, with the first novel targets added to AstraZeneca's portfolio for both CKD and IPF.
  • Anne Phelan, Chief Science Officer at BenevolentAI, commented, "Our collaboration with AstraZeneca represents the future of drug discovery.
  • Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, commented, "Systemic lupus erythematosus and heart failure are debilitating diseases with high unmet patient needs.

SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong an

Retrieved on: 
Tuesday, January 11, 2022 - 7:55am

The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".

Key Points: 
  • The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".
  • In addition, SN1011, a key product of the Company, completed its phase I last subject last visit in China in July last year.
  • That reflects the capital market's recognition of the value, management and growth potential of the Company and is a great encouragement to the Company.
  • The selection of the "6th Hong Kong Golden Stocks Awards" was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities.

Avolon Continues Expansion of its Fleet and Customer Base In 2021

Retrieved on: 
Monday, January 10, 2022 - 12:00pm

Avolon, the international aircraft leasing company, issues an update for the fourth quarter (Q4) and 2021 full year (FY).

Key Points: 
  • Avolon, the international aircraft leasing company, issues an update for the fourth quarter (Q4) and 2021 full year (FY).
  • 2021 saw Avolon make its landmark investment in zero-emissions aircraft.
  • We look forward to continuing to work with our customers to decarbonise air travel and work towards a net zero carbon economy.
  • Avolon is the worlds second largest aircraft leasing business with an owned, managed and committed fleet, as of 31 December 2021 of 824 aircraft.

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

Retrieved on: 
Tuesday, January 4, 2022 - 5:48pm

The Journal of Clinical Investigation is the premier venue for discoveries in basic and clinical biomedical science that will advance the practice of medicine.

Key Points: 
  • The Journal of Clinical Investigation is the premier venue for discoveries in basic and clinical biomedical science that will advance the practice of medicine.
  • More targeted therapies are urgently needed to effectively treat LN, as well as other T cell mediated diseases, said Dr. Putterman.
  • To establish the role of the CD6-ALCAM pathway in disease pathogenesis, the effect of CD6 blockade in animal models of SLE/LN was investigated.
  • Combined, these data further support uALCAM as a biomarker that distinguishes active lupus nephritis and validates targeting the CD6-ALCAM pathway to treat SLE and LN.

First commercial and exclusive agreement signed between 'Teva Israel' and 'Cannbit-Tikun Olam' - for marketing and distribution of medical cannabis oil

Retrieved on: 
Monday, December 27, 2021 - 12:00pm

The oils are based on strains developed by Cannbit-Tikun Olam and selected exclusively by Teva Israel due to their safety profile and strong therapeutic efficacy.

Key Points: 
  • The oils are based on strains developed by Cannbit-Tikun Olam and selected exclusively by Teva Israel due to their safety profile and strong therapeutic efficacy.
  • In the future, and to the extent possible, the cannabis oils will also be marketed by Teva in Ukraine, where the government is currently developing regulation.
  • In these agreements, and specifically the agreement with Teva, Cannbit-Tikun Olam continues to establish its position as the leading company in the medical cannabis market.
  • Tikun Olam-Cannbit is Israel's top cannabis supplier, a leader in clinical research and recognized as a pioneer in the modern medical cannabis industry.